Cook Children’s Medical Center in Fort Worth, Texas became the first hospital in the nation in 2016 to house a life-saving investigational drug called miltefosine (trade name, Impavido) used to treat...

Orlando-based specialty pharmaceutical company, Profounda announced it has received the US Food and Drug Administration’s Orphan Drug Designation for the use of Impavido (miltefosine) to treat Granulomatous...

Last week, we learned of a miracle of sorts. Florida Hospital for Children in Orlando announced that 16-year-old Sebastian Deleon had survived an infection with the amoebic parasite, Naegleria fowleri,...

In a follow-up on the case of Naegleria fowleri infection in South Carolina recently reported, the identification of the patient is now known– 11-year-old Hannah Katherine Collins, according to...

Kyle Gracin Lewis died at Cook Children’s Medical Center in the summer of 2010, from the Primary Amoebic Meningoencephalitis (PAM), the brain infection caused by the water-born amoeba, known as Naegleria...

The U.S. Food and Drug Administration recently approved Impavido (miltefosine) to treat a tropical disease called leishmaniasis. Leishmaniasis is a disease caused by Leishmania, a parasite which is transmitted...